BNC2

Across TCGA pan-cancer cohorts, BNC2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BNC2 data layer compared with 22 for mass-spec protein and 12 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher BNC2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated BNC2 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

GBM, PDAC, and LSCC are the cancer types where BNC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.256	0.505	.003	14	view →
PDAC	OS	Median	All	0.465	0.720	.015	4	view →
LSCC	OS	Tertile	III,IV	0.928	0.495	.042	4	view →
CCRCC	DFS	Quartile	III,IV	0.233	0.887	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

BNC2–GBM (OS)

Open the GBM breakdown →